

31 October 2017

Corrected Appendix 3Y

Optiscan Imaging Limited (OIL) provides the attached corrected Appendix 3Y for Mr Peter Francis in relation to the Appendix 3Y which was lodged on 22 December 2016. It is noted that the previously lodged Appendix 3Y inadvertently included options issued to a nominee of Mr Francis which he does not control or have a relevant interest.

The attached corrected Appendix 3Y reflects the correct position as at 22 December 2017.

For further information, contact:

Justin Mouchacca
Company Secretary

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical and research markets.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OPTISCAN IMAGING LIMITED
ABN	81 077 771 987

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	PETER DAMIAN FRANCIS
Date of last notice	3 MAY 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Beneficial interest in: Francis Family Superannuation Fund
Date of change	22 December 2016
No. of securities held prior to change	Nil
Class	(a) Unlisted Options with exercise price of \$0.025 and expiry date of 28 November 2019. (b) Unlisted Options with exercise price of \$0.05 and expiry date of 28 November 2019. (c) Unlisted Options with exercise price of \$0.075 and expiry date of 28 November 2019.
Number acquired	Francis Family Superannuation Fund (a) 500,000 Unlisted Options (b) 500,000 Unlisted Options (c) 500,000 Unlisted Options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	1,500,000 Unlisted Options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Option issue approved by shareholders on 25 November 2016

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	No
If prior written clearance was provided, on what date was this provided?	No

+ See chapter 19 for defined terms.